KEYNOTE-564
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
KEYNOTE-564
Apr 20, 2024, 06:03 |
Insight
Toni Choueiri: The long-awaited OS results from KEYNOTE-564 are out at the New England Journal of Medicine!
Toni Choueiri shared on X/Twitter: "The long-awaited OS results from KEYNOTE-564 are out at the New…
Feb 13, 2024, 02:14 |
Blog
María Natalia Gandur Quiroga: Key Advances in Prostate, Kidney, and Bladder Cancers Unveiled at GU24
María Natalia Gandur Quiroga shared a post on LinkedIn: "Key Advances in Prostate, Kidney, and Bladder…
Jan 29, 2024, 17:46 |
Insight
Roberto Iacovelli: Different results from 2 phase 3 studies on adjuvant IO for mRCC... what's the reason?
Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome…
Nov 5, 2023, 18:48 |
Drugs
Toni Choueiri: Pembrolizumab hits OVERALL SURVIVAL in KYN-564 adjuvant study in Kidney Cancer!!!
Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer…
All:
4
Posts:
1 - 100
OncoDaily at ASCO 2024: OncoDaily Party, Yvonne Award and much more
Tedros Adhanom Ghebreyesus received University of Nicosia’s Honorary Doctorate
Lisa A. Lacasse: A major milestone towards Congress passing the bipartisan MCED Act
July is Sarcoma Awareness Month
25 Posts You Should Not Miss From ESMOGI24!
Facebook
RSS Feed
Twitter
Linkedin
Youtube